Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Animal Drug User Fee Cover Sheet, Form 3546, 7866-7867 [2011-3167]
Download as PDF
7866
Federal Register / Vol. 76, No. 29 / Friday, February 11, 2011 / Notices
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Dated: February 7, 2011.
Leslie Kux,
Acting Assistant Commissioner for Policy.
Food and Drug Administration
[FR Doc. 2011–3031 Filed 2–10–11; 8:45 am]
In
compliance with 44 U.S.C. 3507, FDA
has submitted the following proposed
collection of information to OMB for
review and clearance.
SUPPLEMENTARY INFORMATION:
BILLING CODE 4160–01–P
[Docket No. 2010–N–0066]
Agency Information Collection
Activities; Announcement of Office of
Management and Budget Approval;
Human Tissue Intended for
Transplantation
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug
Administration (FDA) is announcing
that a collection of information entitled
‘‘Human Tissue Intended for
Transplantation’’ has been approved by
the Office of Management and Budget
(OMB) under the Paperwork Reduction
Act of 1995.
SUMMARY:
FOR FURTHER INFORMATION CONTACT:
Johnny Vilela, Office of Information
Management, Food and Drug
Administration, 1350 Piccard Dr., PI50–
400B, Rockville, MD 20850, (301) 796–
7651, Juanmanuel.Vilela@fda.hhs.gov.
In the
Federal Register of August 2, 2010 (75
FR 45127), the Agency announced that
the proposed information collection had
been submitted to OMB for review and
clearance under 44 U.S.C. 3507. An
Agency may not conduct or sponsor,
and a person is not required to respond
to, a collection of information unless it
displays a currently valid OMB control
number. OMB has now approved the
information collection and has assigned
OMB control number 0910–0302. The
approval expires on January 31, 2014. A
copy of the supporting statement for this
information collection is available on
the Internet at https://www.reginfo.gov/
public/do/PRAMain.
SUPPLEMENTARY INFORMATION:
Animal Drug User Fee Cover Sheet;
FDA Form 3546—(OMB Control
Number 0910–0539)—Extension
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2010–N–0600]
Agency Information Collection
Activities; Submission for Office of
Management and Budget Review;
Comment Request; Animal Drug User
Fee Cover Sheet, Form 3546
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug
Administration (FDA) is announcing
that a proposed collection of
information has been submitted to the
Office of Management and Budget
(OMB) for review and clearance under
the Paperwork Reduction Act of 1995.
DATES: Fax written comments on the
collection of information by March 14,
2011.
ADDRESSES: To ensure that comments on
the information collection are received,
OMB recommends that written
comments be faxed to the Office of
Information and Regulatory Affairs,
OMB, Attn: FDA Desk Officer, FAX:
202–395–7285, or e-mailed to
oira_submission@omb.eop.gov. All
comments should be identified with the
OMB control number 0910–0539. Also
include the FDA docket number found
in brackets in the heading of this
document.
FOR FURTHER INFORMATION CONTACT:
Johnny Vilela, Office of Information
Management, Food and Drug
Administration, 1350 Piccard Dr., PI50–
400B, Rockville, MD 20850, 301–796–
7651, Juanmanuel.vilela@fda.hhs.gov.
SUMMARY:
Under section 740 of the Federal
Food, Drug, and Cosmetic Act (the
FD&C Act) (21 U.S.C. 379j-12), as
amended by the Animal Drug User Fee
Act (ADUFA), FDA has the authority to
assess and collect for certain animal
drug user fees. Because the submission
of user fees concurrently with
applications and supplements is
required, review of an application
cannot begin until the fee is submitted.
The types of fees that require a cover
sheet are certain animal drug
application fees and certain
supplemental animal drug application
fees. The cover sheet (FDA Form 3546)
is designed to provide the minimum
necessary information to determine
whether a fee is required for the review
of an application or supplement, to
determine the amount of the fee
required, and to assure that each animal
drug user fee payment and each animal
drug application for which payment is
made is appropriately linked to the
payment that is made. The form, when
completed electronically, will result in
the generation of a unique payment
identification number used in tracking
the payment. FDA will use the
information collected to initiate
administrative screening of new animal
drug applications and supplements to
determine if payment has been received.
In the Federal Register of November
29, 2010 (75 FR 73103), FDA published
a 60-day notice requesting public
comment on the proposed collection of
information. No comments were
received.
FDA estimates the burden of this
collection of information as follows:
TABLE 1—ESTIMATED ANNUAL REPORTING BURDEN 1
FD&C Act Section amended by ADUFA
No. of respondents
Annual frequency per response
Total annual
responses
Hours per response
Total hours
740(a)(1) FDA Form 3546 (Cover Sheet) ...........................
76
1
76
1
76
........................
........................
........................
........................
76
jlentini on DSKJ8SOYB1PROD with NOTICES
Total ..............................................................................
1 There
are no capital costs or operating and maintenance costs associated with this collection of information.
Respondents to this collection of
information are new animal drug
applicants or manufacturers. Based on
FDA’s database system, there are an
VerDate Mar<15>2010
18:55 Feb 10, 2011
Jkt 223001
estimated 140 manufacturers of
products or sponsors of new animal
drugs potentially subject to ADUFA.
However, not all manufacturers or
PO 00000
Frm 00060
Fmt 4703
Sfmt 4703
sponsors will have any submissions in
a given year and some may have
multiple submissions. The total number
of annual responses is based on the
E:\FR\FM\11FEN1.SGM
11FEN1
Federal Register / Vol. 76, No. 29 / Friday, February 11, 2011 / Notices
number of submissions received by FDA
in fiscal year 2008. The estimated hours
per response are based on past FDA
experience with the various
submissions. The hours per response are
based on the average of these estimates.
Dated: February 8, 2011.
Leslie Kux,
Acting Assistant Commissioner for Policy.
[FR Doc. 2011–3167 Filed 2–10–11; 8:45 am]
BILLING CODE 4160–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Proposed Collection; Comment
Request; Cancer Biomedical
Informatics Grid® (caBIG®) Support
Service Provider (SSP) Program (NCI)
In compliance with the
requirement of Section 3506(c)(2)(A) of
the Paperwork Reduction Act of 1995,
for opportunity for public comment on
proposed data collection projects, the
National Cancer Institute (NCI), the
National Institutes of Health (NIH) will
publish periodic summaries of proposed
projects to be submitted to the Office of
Management and Budget (OMB) for
review and approval.
SUMMARY:
Proposed Collection: Title: cancer
Biomedical Informatics Grid ® (caBIG ®)
Support Service Provider (SSP) Program
(NCI). Type of Information Collection
Request: Existing Collection in Use
Without an OMB Number. Need and
Use of Information Collection: The NCI
Center for Biomedical Informatics and
Information Technology (CBIIT)
launched the enterprise phase of the
caBIG ® initiative in early 2007 with an
emphasis on widespread institutional
adoption of the program and tools. This
emphasis on adoption has generated an
expanding community with diverse
needs for support, which are met
through the resources available through
the caBIG ® Enterprise Support Network
(ESN), including the caBIG ® Support
Service Provider (SSP) Program. The
caBIG ® SSPs provide caBIG ® end-users
with the freedom to match what caBIG ®
has to offer to their unique
organizational goals and needs, so
having this customized support option
available is critically important to
advancing the goals of the caBIG ®
program. caBIG ® SSP applicants are
evaluated against well-defined criteria
published in the SSP Program
Announcement and must successfully
demonstrate that they have the technical
capabilities, staffing and scalability,
geographic coverage (when applicable),
and the domain expertise in
7867
biomedicine to effectively serve caBIG ®
users. The information submitted by
SSP applicants enables NCI to
determine whether such applicants are
qualified to enter into trademark license
negotiations with NCI to use the caBIG ®
trademarks in connection with their
services and become designated as
caBIG ® SSPs. Thus, the collection of
information from SSP applicants is
critical to both ensuring that the goals
and objectives of the caBIG ® program
will be maintained and furthered by the
organizations designated as SSPs and
facilitating NCI’s ability to exercise
appropriate stewardship of the caBIG ®
trademarks. Sections 410 and 411 of the
Public Health Service Act (42 U.S.C. 285
and 285a) authorize the collection of the
information. Frequency of Response:
once for the applicants. caBIG ® SSP
applications are accepted on a rolling
basis and reviewed several times a year.
Affected Public: Private sector including
Business or other for-profits and not-forprofit organizations and institutions.
Type of Respondents: Technical
representatives of commercial, academic
or not-for-profit organizations. The
annual reporting burden is estimated at
360 hours.
There are no Capital Costs, Operating
Costs, and/or Maintenance Costs to
report.
A.12—1 ESTIMATES OF ANNUAL BURDEN HOURS
Number of
respondents
Type of respondents
Frequency of
response
Average time
per response
(minutes/hour)
Annual burden
hours
336
360
14
1
Nonprofit Organizations ...................................................................................
1
1
1440/60
(24 hours)
1440/60
(24 hours)
Totals ........................................................................................................
jlentini on DSKJ8SOYB1PROD with NOTICES
Commercial Organizations ..............................................................................
15
........................
........................
Request for Comments: Written
comments and/or suggestions from the
public and affected agencies are invited
on one or more of the following points:
(1) Evaluate whether the proposed
collection of information is necessary
for the proper performance of the
function of the agency, including
whether the information will have
practical utility; (2) Evaluate the
accuracy of the agency’s estimate of the
burden of the proposed collection of
information, including the validity of
the methodology and assumptions used;
(3) Enhance the quality, utility, and
clarity of the information to be
collected; and (4) Minimize the burden
of the collection of information on those
who are to respond, including the use
VerDate Mar<15>2010
18:55 Feb 10, 2011
Jkt 223001
of appropriate automated, electronic,
mechanical, or other technological
collection techniques or other forms of
information technology.
To
request more information on the
proposed project or to obtain a copy of
the data collection plans and
instruments, contact John Speakman,
NCI CBIIT Chief Program Officer, Center
for Biomedical Informatics and
Information Technology, National
Cancer Institute, NIH, DHHS, 2115 E.
Jefferson Street, Suite 6000, Rockville,
MD 20892 or call non-toll-free number
301–451–8786 or e-mail your request,
including your address to:
john.speakman@nih.gov.
FOR FURTHER INFORMATION CONTACT:
PO 00000
Frm 00061
Fmt 4703
Sfmt 9990
24
Comments Due Date: Comments
regarding this information collection are
best assured of having their full effect if
received within 60 days of the date of
this publication.
Dated: February 4, 2011.
Vivian Horovitch-Kelley,
NCI Project Clearance Liaison, National
Institutes of Health.
[FR Doc. 2011–3144 Filed 2–10–11; 8:45 am]
BILLING CODE 4140–01–P
E:\FR\FM\11FEN1.SGM
11FEN1
Agencies
[Federal Register Volume 76, Number 29 (Friday, February 11, 2011)]
[Notices]
[Pages 7866-7867]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2011-3167]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2010-N-0600]
Agency Information Collection Activities; Submission for Office
of Management and Budget Review; Comment Request; Animal Drug User Fee
Cover Sheet, Form 3546
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is announcing that a
proposed collection of information has been submitted to the Office of
Management and Budget (OMB) for review and clearance under the
Paperwork Reduction Act of 1995.
DATES: Fax written comments on the collection of information by March
14, 2011.
ADDRESSES: To ensure that comments on the information collection are
received, OMB recommends that written comments be faxed to the Office
of Information and Regulatory Affairs, OMB, Attn: FDA Desk Officer,
FAX: 202-395-7285, or e-mailed to oira_submission@omb.eop.gov. All
comments should be identified with the OMB control number 0910-0539.
Also include the FDA docket number found in brackets in the heading of
this document.
FOR FURTHER INFORMATION CONTACT: Johnny Vilela, Office of Information
Management, Food and Drug Administration, 1350 Piccard Dr., PI50-400B,
Rockville, MD 20850, 301-796-7651, Juanmanuel.vilela@fda.hhs.gov.
SUPPLEMENTARY INFORMATION: In compliance with 44 U.S.C. 3507, FDA has
submitted the following proposed collection of information to OMB for
review and clearance.
Animal Drug User Fee Cover Sheet; FDA Form 3546--(OMB Control Number
0910-0539)--Extension
Under section 740 of the Federal Food, Drug, and Cosmetic Act (the
FD&C Act) (21 U.S.C. 379j-12), as amended by the Animal Drug User Fee
Act (ADUFA), FDA has the authority to assess and collect for certain
animal drug user fees. Because the submission of user fees concurrently
with applications and supplements is required, review of an application
cannot begin until the fee is submitted. The types of fees that require
a cover sheet are certain animal drug application fees and certain
supplemental animal drug application fees. The cover sheet (FDA Form
3546) is designed to provide the minimum necessary information to
determine whether a fee is required for the review of an application or
supplement, to determine the amount of the fee required, and to assure
that each animal drug user fee payment and each animal drug application
for which payment is made is appropriately linked to the payment that
is made. The form, when completed electronically, will result in the
generation of a unique payment identification number used in tracking
the payment. FDA will use the information collected to initiate
administrative screening of new animal drug applications and
supplements to determine if payment has been received.
In the Federal Register of November 29, 2010 (75 FR 73103), FDA
published a 60-day notice requesting public comment on the proposed
collection of information. No comments were received.
FDA estimates the burden of this collection of information as
follows:
Table 1--Estimated Annual Reporting Burden \1\
--------------------------------------------------------------------------------------------------------------------------------------------------------
Annual
FD&C Act Section amended by ADUFA No. of frequency per Total annual Hours per Total hours
respondents response responses response
--------------------------------------------------------------------------------------------------------------------------------------------------------
740(a)(1) FDA Form 3546 (Cover Sheet).............................. 76 1 76 1 76
------------------------------------------------------------------------------------
Total.......................................................... ............... ............... ............... ............... 76
--------------------------------------------------------------------------------------------------------------------------------------------------------
\1\ There are no capital costs or operating and maintenance costs associated with this collection of information.
Respondents to this collection of information are new animal drug
applicants or manufacturers. Based on FDA's database system, there are
an estimated 140 manufacturers of products or sponsors of new animal
drugs potentially subject to ADUFA. However, not all manufacturers or
sponsors will have any submissions in a given year and some may have
multiple submissions. The total number of annual responses is based on
the
[[Page 7867]]
number of submissions received by FDA in fiscal year 2008. The
estimated hours per response are based on past FDA experience with the
various submissions. The hours per response are based on the average of
these estimates.
Dated: February 8, 2011.
Leslie Kux,
Acting Assistant Commissioner for Policy.
[FR Doc. 2011-3167 Filed 2-10-11; 8:45 am]
BILLING CODE 4160-01-P